Neulasta (Pegfilgrastim) and Biosimilar Market Revenue was valued at USD 4.5 Billion in 2024 and is estimated to reach USD 9.2 Billion by 2033, growing at a CAGR of 8.5% from 2026 to 2033.
The global market for Neulasta (Pegfilgrastim) and its biosimilars was valued at approximately USD 7.5 billion in 2022 and is projected to grow at a CAGR of around 8.5% from 2023 to 2030. The increasing prevalence of cancer treatments requiring neutropenia management, along with the growing acceptance of biosimilars due to their cost effectiveness, is driving the markets growth. The biosimilars segment is experiencing a significant rise, particularly in developed regions, where healthcare systems are shifting towards biosimilar adoption due to the high costs associated with branded biologics like Neulasta. By 2030, the market is expected to reach around USD 15 billion globally, reflecting an increased market penetration and rising healthcare expenditure. The demand for cost efficient alternatives and growing support for biosimilars from regulatory agencies are expected to accelerate this expansion. Furthermore, the market’s growth is also driven by the increasing number of cancer patients undergoing chemotherapy, particularly in emerging markets.
In terms of regional analysis, North America holds the largest market share in 2022, contributing over USD 3 billion, with a substantial growth rate projected at a CAGR of 8.2%. The regions growth is primarily driven by the high adoption rate of biosimilars and advancements in healthcare infrastructure. Europe follows closely, contributing approximately USD 2.2 billion in 2022, with a projected CAGR of 9% due to favorable regulations and increasing healthcare access. The Asia Pacific region is expected to witness the highest growth rate, with a CAGR of 10% over the forecast period, owing to rising cancer incidence and the increasing healthcare expenditure in countries like India and China. Latin America and the Middle East & Africa are also anticipated to experience gradual growth, with an increasing focus on affordable cancer care and biosimilar adoption in the coming years.
Get | Download Sample Copy with TOC, Graphs & List of Figures @ http://verifiedmarketreports.com/download-sample/?rid=401406&utm_source=Pulse_G_April&utm_medium=212
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase Of This Report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=401406&utm_source=Pulse_G_April&utm_medium=212
Growing demand for below applications around the world has had a direct impact on the growth of the Global Neulasta (Pegfilgrastim) and Biosimilar Market
Pegfilgrastim
Biosimilar Pegfilgrastim
Hospitals
Clinics
Homecare Settings
Cancer Treatment
Hematological Disorders
Other Medical Conditions
Injectable
Prefilled Syringe
Vial
Direct Sales
Third-Party Distributors
Online Pharmacies
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ https://www.verifiedmarketreports.com/product/neulasta-pegfilgrastim-and-biosimilar-market/
1. Introduction of the Global Neulasta (Pegfilgrastim) and Biosimilar Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Neulasta (Pegfilgrastim) and Biosimilar Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Neulasta (Pegfilgrastim) and Biosimilar Market, By Type
6. Global Neulasta (Pegfilgrastim) and Biosimilar Market, By Application
7. Global Neulasta (Pegfilgrastim) and Biosimilar Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. Global Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/